Edition:
United Kingdom

Melinta Therapeutics Inc (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

3.78USD
19 Oct 2018
Change (% chg)

$-0.02 (-0.53%)
Prev Close
$3.80
Open
$3.80
Day's High
$3.96
Day's Low
$3.71
Volume
64,462
Avg. Vol
102,957
52-wk High
$18.15
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

Melinta Therapeutics And Menarini Group Enter Commercial Agreement
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS AND MENARINI GROUP ENTER COMMERCIAL AGREEMENT FOR VABOMERE™ (MEROPENEM AND VABORBACTAM), ORBACTIV® (ORITAVANCIN) AND MINOCIN® (MINOCYCLINE) FOR INJECTION IN 68 COUNTRIES.MELINTA THERAPEUTICS, INC. - TOTAL CONSIDERATION OF UP TO $265 MILLION (INCLUDING POTENTIAL ROYALTIES).MELINTA THERAPEUTICS- WILL RECEIVE UPFRONT LICENSING FEE, ADDITIONAL APPROVAL AND SALES-BASED MILESTONE PAYMENTS, AND POTENTIAL ROYALTY PAYMENTS.MELINTA THERAPEUTICS, INC. - EXPANDS ON EXISTING COMMERCIAL AND CO-DEVELOPMENT AGREEMENT FOR BAXDELA(®) (DELAFLOXACIN).MELINTA THERAPEUTICS - TO MAINTAIN RIGHTS FOR VABOMERE, ORBACTIV AND MINOCIN FOR INJECTION IN U.S..  Full Article

Melinta Therapeutics Prices Public Offering Of 22.0 Mln Shares At $5/Share
Thursday, 24 May 2018 

May 23 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 22.0 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Melinta Therapeutics Announces Proposed Offering Of Common Stock
Monday, 21 May 2018 

May 21 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.MELINTA THERAPEUTICS - COMMENCED UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK TO RAISE AGGREGATE PROCEEDS OF APPROXIMATELY $75 MILLION.MELINTA THERAPEUTICS - INTENDS TO USE PROCEEDS FROM PROPOSED SALE OF ITS SHARES TO INVEST IN PORTFOLIO OF ANTIBIOTICS, AMONG OTHERS.  Full Article

Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA.  Full Article

Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING.  Full Article

Deerfield Management Reports 10 Pct Passive Stake In Melinta Therapeutics
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Melinta Therapeutics Inc ::DEERFIELD MANAGEMENT COMPANY LP REPORTS A 10 PCT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN 5 - SEC FILING.  Full Article

Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Melinta Therapeutics, Inc. ::MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY.  Full Article

Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Medicines Co ::THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS.MEDICINES - TO SELL INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS FOR $270 MILLION IN UPFRONT CONSIDERATION AND GUARANTEED PAYMENTS.MEDICINES - DEAL INCLUDES TIERED ROYALTY PAYMENTS OF 5% TO 25% ON WORLDWIDE NET SALES OF VABOMERE, ORBACTIV AND MINOCIN IV, AMONG OTHER THINGS.MEDICINES CO - MELINTA TO PAY DEAL CONSIDERATION, INCLUDING $165 MILLION IN CASH, PAID AT CLOSING, MELINTA SHARES WITH A MARKET OF $55 MILLION, AMONG OTHERS.MEDICINES CO - ‍CONCURRENT WITH EXECUTION OF DEAL, CO RECEIVED BINDING COMMITMENT FROM DEERFIELD MANAGEMENT AFFILIATE.MEDICINES CO - DEERFIELD MANAGEMENT ‍AFFILIATE COMMITTED TO PROVIDE FINANCING TO MELINTA IN CONNECTION WITH DEAL,TO PROVIDE A $100 MILLION CREDIT FACILITY​.  Full Article

‍Melinta Therapeutics, Cempra name Daniel Wechsler as CEO of combined company
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Cempra Inc :‍Melinta Therapeutics says co, Cempra announced that their selection committee selected Dan Wechsler to be president and CEO of combined company​.  Full Article

Cempra appoints David Zaccardelli as acting CEO
Monday, 12 Dec 2016 

Cempra Inc : Cempra inc - appointed board member David Zaccardelli, pharm.d., as acting chief executive officer . Cempra inc - promoted David Moore to newly created position of president and chief commercial officer, effective immediately .Cempra appoints David Zaccardelli as acting chief executive officer, promotes chief commercial officer David Moore to president.  Full Article